TY - JOUR
T1 - Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass
AU - Jonsson, Isabella
AU - Bojsen-Møller, Kirstine N
AU - Kristiansen, Viggo B
AU - Veedfald, Simon
AU - Wewer Albrechtsen, Nicolai J
AU - Clausen, Trine R
AU - Kuhre, Rune E
AU - Rehfeld, Jens F
AU - Holst, Jens J
AU - Madsbad, Sten
AU - Svane, Maria S
N1 - Copyright © 2021 Jonsson, Bojsen-Møller, Kristiansen, Veedfald, Wewer Albrechtsen, Clausen, Kuhre, Rehfeld, Holst, Madsbad and Svane.
PY - 2021/5/14
Y1 - 2021/5/14
N2 - Background: Altered bile acid (BA) turnover has been suggested to be involved in the improved glucose regulation after Roux-en-Y gastric bypass (RYGB), possibly via stimulation of GLP-1 secretion. We investigated the role of exogenous as well as endogenous BAs for GLP-1 secretion after RYGB by administering chenodeoxycholic acid (CDCA) and the BA sequestrant colesevelam (COL) both in the presence and the absence of a meal stimulus.Methods: Two single-blinded randomized cross-over studies were performed. In study 1, eight RYGB operated participants ingested 200 ml water with 1) CDCA 1.25 g or 2) CDCA 1.25 g + colesevelam 3.75 g on separate days. In study 2, twelve RYGB participants ingested on separate days a mixed meal with addition of 1) CDCA 1.25 g, 2) COL 3.75 g or 3) COL 3.75 g × 2, or 4) no additions.Results: In study 1, oral intake of CDCA increased circulating BAs, GLP-1, C-peptide, glucagon, and neurotensin. Addition of colesevelam reduced all responses. In study 2, addition of CDCA enhanced meal-induced increases in plasma GLP-1, glucagon and FGF-19 and lowered plasma glucose and C-peptide concentrations, while adding colesevelam lowered circulating BAs but did not affect meal-induced changes in plasma glucose or measured gastrointestinal hormones.Conclusion: In RYGB-operated persons, exogenous CDCA enhanced meal-stimulated GLP-1 and glucagon secretion but not insulin secretion, while the BA sequestrant colesevelam decreased CDCA-stimulated GLP-1 secretion but did not affect meal-stimulated GLP-1, C-peptide or glucagon secretion, or glucose tolerance. These findings suggest a limited role for endogenous bile acids in the acute regulation of postprandial gut hormone secretion or glucose metabolism after RYGB.
AB - Background: Altered bile acid (BA) turnover has been suggested to be involved in the improved glucose regulation after Roux-en-Y gastric bypass (RYGB), possibly via stimulation of GLP-1 secretion. We investigated the role of exogenous as well as endogenous BAs for GLP-1 secretion after RYGB by administering chenodeoxycholic acid (CDCA) and the BA sequestrant colesevelam (COL) both in the presence and the absence of a meal stimulus.Methods: Two single-blinded randomized cross-over studies were performed. In study 1, eight RYGB operated participants ingested 200 ml water with 1) CDCA 1.25 g or 2) CDCA 1.25 g + colesevelam 3.75 g on separate days. In study 2, twelve RYGB participants ingested on separate days a mixed meal with addition of 1) CDCA 1.25 g, 2) COL 3.75 g or 3) COL 3.75 g × 2, or 4) no additions.Results: In study 1, oral intake of CDCA increased circulating BAs, GLP-1, C-peptide, glucagon, and neurotensin. Addition of colesevelam reduced all responses. In study 2, addition of CDCA enhanced meal-induced increases in plasma GLP-1, glucagon and FGF-19 and lowered plasma glucose and C-peptide concentrations, while adding colesevelam lowered circulating BAs but did not affect meal-induced changes in plasma glucose or measured gastrointestinal hormones.Conclusion: In RYGB-operated persons, exogenous CDCA enhanced meal-stimulated GLP-1 and glucagon secretion but not insulin secretion, while the BA sequestrant colesevelam decreased CDCA-stimulated GLP-1 secretion but did not affect meal-stimulated GLP-1, C-peptide or glucagon secretion, or glucose tolerance. These findings suggest a limited role for endogenous bile acids in the acute regulation of postprandial gut hormone secretion or glucose metabolism after RYGB.
KW - RYGB
KW - Roux-en-Y gastric bypass
KW - bile acids
KW - colesevelam
KW - glucagon-like peptide 1
KW - Glucagon/blood
KW - Single-Blind Method
KW - Gastric Bypass
KW - Neurotensin/blood
KW - Humans
KW - Middle Aged
KW - Blood Glucose
KW - Male
KW - Obesity, Morbid/blood
KW - Postprandial Period
KW - Adult
KW - Female
KW - Glucose/metabolism
KW - Glucagon-Like Peptide 1/blood
KW - Bile Acids and Salts/blood
KW - C-Peptide/blood
KW - Colesevelam Hydrochloride/therapeutic use
UR - http://www.scopus.com/inward/record.url?scp=85107047889&partnerID=8YFLogxK
U2 - 10.3389/fendo.2021.681116
DO - 10.3389/fendo.2021.681116
M3 - Journal article
C2 - 34084153
SN - 1664-2392
VL - 12
SP - 1
EP - 11
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
M1 - 681116
ER -